AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
Analyst coverage unavailable
Fundamentals
Fundamentals institutional score is 100 using growth durability 100.0.
Valuation
Valuation institutional score is 1 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
No usable analyst target or recommendation data was available.
Technical Structure
Technicals institutional score is 0 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 3 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and valuation provide support, while technical structure and market sentiment remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 63.6% above historical median. Valuation is declining — currently in the strongly overvalued zone (z-score: +1.94). Confidence: 73%.
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
27.27
Current
46.39
Overvalued
34.42
Undervalued
24.55
5Y Average
14.00
Current
23.48
Overvalued
16.64
Undervalued
10.79
5Y Average
1.33
Current
2.22
Overvalued
1.52
Undervalued
1.13
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 31.2x Undervalued | -53% vs avg | +22.1% |
CONCORD BIOTECH LIMITED CONCORDBIOPharmaceuticals | +26.2% | 24.8% | 48.8x Undervalued | -27% vs avg | -14.9% |
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 43.8x Undervalued | -34% vs avg | +45.4% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.7x Undervalued | -34% vs avg | -25.8% |
ASTRAZENECA PHARMA IND LT ASTRAZENPharmaceuticals | +20.4% | 8.2% | 107.4x Premium | +62% vs avg | -6.9% |
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 28.0x Undervalued | -58% vs avg | +43.4% |
COHANCE LIFESCIENCES LTD COHANCEPharmaceuticals | -23.1% | 5.0% | 162.0x Premium | +144% vs avg | -52.7% |
MOREPEN LAB. LTD trades at a discount (45.8x vs peer avg 66.4x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include CAPLIN POINT LAB LTD., CONCORD BIOTECH LIMITED, AKUMS DRUGS AND PHARMA L — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹541 CrJun 2026Latest net profit
₹54 CrJun 2026Latest EPS
₹0.99Jun 2026Net margin
15.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 369 | 381 | 395 | 393 | 386 | 384 | 403 | 382 | 391 | 370 | 458 | 463 | 541 |
| Expenses + | 344 | 352 | 344 | 336 | 337 | 341 | 372 | 352 | 372 | 342 | 416 | 440 | 461 |
| Operating Profit | 25 | 30 | 51 | 56 | 49 | 43 | 32 | 30 | 19 | 28 | 42 | 23 | 80 |
| OPM % | 7% | 8% | 13% | 14% | 13% | 11% | 8% | 8% | 4.8% | 8% | 9% | 5% | 15% |
| Other Income + | 2 | 3 | 4 | 4 | 3 | 5 | 5 | 3 | 4 | 6 | 4 | 9 | 5 |
| Interest | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 4 | 4 | 4 | 4 | 4 | 5 |
| Depreciation | 5 | 5 | 6 | 7 | 4 | 4 | 5 | 12 | 8 | 11 | 10 | 1 | 8 |
| Profit before tax | 22 | 27 | 47 | 53 | 47 | 43 | 30 | 17 | 11 | 19 | 31 | 28 | 72 |
| Tax % | 27% | 27% | 25% | 24% | 26% | 26% | 25% | 31% | 29% | 24% | 25% | 27% | 25% |
| Net Profit + | 16 | 20 | 35 | 40 | 35 | 32 | 23 | 12 | 8 | 14 | 24 | 20 | 54 |
| EPS in Rs | 0.31 | 0.39 | 0.69 | 0.78 | 0.69 | 0.58 | 0.41 | 0.22 | 0.15 | 0.26 | 0.43 | 0.37 | 0.99 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Monitoring Agency Report